Capricor Therapeutics, Inc. Sustainability Profile
Capricor Therapeutics, Inc., a pioneering biotechnology firm headquartered in the United States, focuses on developing innovative therapies for serious medical conditions. Founded in 2000, the company has made significant strides in the fields of regenerative medicine and cell therapy, particularly in the treatment of cardiovascular diseases and Duchenne muscular dystrophy (DMD). Capricor's flagship product, CAP-1002, is a unique allogeneic cardiosphere-derived cell therapy that aims to improve heart function in patients with advanced heart failure. The company has garnered attention for its robust clinical trial results and commitment to advancing therapeutic options in underserved patient populations. With a strong market position and a dedication to scientific excellence, Capricor Therapeutics continues to lead the way in transforming the landscape of regenerative medicine.
DitchCarbon Score
How does Capricor Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Capricor Therapeutics, Inc.'s score of 23 is lower than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Capricor Therapeutics, Inc.'s reported carbon emissions
Capricor Therapeutics, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or commitments to climate initiatives, such as those outlined by the Science Based Targets initiative (SBTi) or other industry standards. Given the lack of emissions data and reduction initiatives, it is unclear how Capricor Therapeutics is addressing climate change or its carbon footprint. The absence of a climate pledge or specific targets suggests that the company may still be in the early stages of developing a comprehensive sustainability strategy. As the industry increasingly prioritises environmental responsibility, it will be essential for Capricor Therapeutics to consider implementing measurable climate commitments in the future.
How Carbon Intensive is Capricor Therapeutics, Inc.'s Industry?
How Carbon Intensive is Capricor Therapeutics, Inc.'s Location?
Capricor Therapeutics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Capricor Therapeutics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
